Bode Lars, Freeze Hudson H
Glycobiology and Carbohydrate Chemistry Program, Burnham Institute for Medical Research, La Jolla, CA 92037, USA.
Biochim Biophys Acta. 2006 Apr;1760(4):547-59. doi: 10.1016/j.bbagen.2005.11.004. Epub 2005 Dec 9.
Protein-losing enteropathy (PLE), the loss of plasma proteins through the intestine, is a life-threatening symptom associated with seemingly unrelated conditions including Crohn's disease, congenital disorder of glycosylation, or Fontan surgery to correct univentricular hearts. Emerging commonalities between these and other disorders led us to hypothesize that PLE develops when genetic insufficiencies collide with simultaneous or sequential environmental insults. Most intriguing is the loss of heparan sulfate (HS) proteoglycans (HSPG) specifically from the basolateral surface of intestinal epithelial cells only during PLE episodes suggesting a direct link to protein leakage. Reasons for HSPG loss are unknown, but genetic insufficiencies affecting HSPG biosynthesis, trafficking, or degradation may be involved. Here, we describe cell-based assays we devised to identify key players contributing to protein leakage. Results from these assays confirm that HS loss directly causes protein leakage, but more importantly, it amplifies the effects of other factors, e.g., cytokines and increased pressure. Thus, HS loss appears to play a central role for PLE. To transfer our in vitro results back to the in vivo situation, we established methods to assess enteric protein leakage in mice and present several genetically deficient strains mimicking intestinal HS loss observed in PLE patients. Preliminary results indicate that mice with haploinsufficient genes involved in HS biosynthesis or HSPG trafficking develop intestinal protein leakage upon additional environmental stress. Our goal is to model PLE in vitro and in vivo to unravel the pathomechanisms underlying PLE, identify patients at risk, and provide them with a safe and effective therapy.
蛋白丢失性肠病(PLE)是指血浆蛋白通过肠道丢失的一种疾病,是一种与包括克罗恩病、先天性糖基化障碍或用于矫正单心室心脏的Fontan手术等看似不相关的病症相关的危及生命的症状。这些疾病与其他疾病之间新出现的共性促使我们提出这样的假设:当基因缺陷与同时或相继发生的环境损伤相互碰撞时,就会发生PLE。最引人关注的是,仅在PLE发作期间,硫酸乙酰肝素(HS)蛋白聚糖(HSPG)会从肠上皮细胞的基底外侧表面特异性丢失,这表明其与蛋白质渗漏存在直接联系。HSPG丢失的原因尚不清楚,但可能涉及影响HSPG生物合成、运输或降解的基因缺陷。在这里,我们描述了我们设计的基于细胞的检测方法,以确定导致蛋白质渗漏的关键因素。这些检测结果证实,HS丢失直接导致蛋白质渗漏,但更重要的是,它会放大其他因素的影响,例如细胞因子和压力增加。因此,HS丢失似乎在PLE中起核心作用。为了将我们的体外研究结果应用到体内情况,我们建立了评估小鼠肠道蛋白质渗漏的方法,并展示了几种模拟PLE患者中观察到的肠道HS丢失的基因缺陷菌株。初步结果表明,参与HS生物合成或HSPG运输的单倍剂量不足基因的小鼠在受到额外的环境压力时会出现肠道蛋白质渗漏。我们的目标是在体外和体内模拟PLE,以阐明PLE的发病机制,识别有风险的患者,并为他们提供安全有效的治疗方法。